Jianing Wang

I am a fourth-year PhD candidate in Biostatistics at Boston University. I also serve as a graduate student fellow at the Rafik B. Hariri Institute for Computing and Computational Science & Engineering at BU, and a graduate student fellow at Boston Medical Center, working in the HIV/HCV epidemiology and outcome research group.

I am interested in developing statistical tools to overcome challenges in public health surveillance and address critical problems in population health and epidemiology. Specifically, I work on developing Bayesian multi-level models for population size estimation and spatial disease mapping that leverage incomplete surveillance data to address tangled epidemiological and social problems, such as the opioid epidemic. Through my research, I have developed methodological research interests in Bayesian methods, small area estimation, spatial statistics, multivariate modeling, indirect methods for population size estimation, and complex computer simulator calibration. I primarily focus on modeling observational data, especially large administrative data, claims data, and electronic health records. I am interested in connecting large-scale health data to clinical trial and genomics data to inform the study design and improve the translational pipeline.

In addition, I work as a dedicated researcher in various interdisciplinary collaborative research that integrates quantitative approaches to improve population health outcomes, promote the equitable clinical practice, and inform clinical decision-making and health policy. I have participated in research on populations with infectious diseases (e.g., HIV and HCV), cancer, and substance use disorders. I am also engaged in research funded by NIH HEAL initiative using innovative methods to help understand the impact of and improve upon policies that affect people who are drug-use with or at high risk for infections of associated diseases. I look forward to applying the developed techniques and advancing the methods in a broader scope of health sciences problems and new diseases and discovering the methodological and practical connections between different contexts.

See all my research projects *
A Spatial Capture-Recapture Approach for Estimating Opioid Use Disorder Prevalence in Small Areas Using Administrative Data
We propose a two-stage Bayesian hierarchical model with spatial smoothing using a capture-recapture data structure to estimate community-specific opioid use disorder (OUD) prevalence. We explicitly model the hidden prevalence of interest and the associated detection model that describes individual detection histories across data sources.
Population size estimation methods using incomplete disease surveillance data
We used multiple individually linked administrative health data to compare the results of stratified capture-recapture analysis and Bayesian multiplier benchmark analysis to estimate OUD prevalence in the Massachusetts population.
Safety Evaluation in Oncology Phase II Basket Trial
We extend the Bayesian hierarchical modeling framework from efficacy assessment studies in basket trial design to characterize the treatment’s safety profile. We propose Bayesian multi-level count models adopting different likelihood options with additional focus placed on the choice of prior for the basket-level standard deviation.

Publications

Search my publications *
(2023). A spatial capture-recapture approach for estimating opioid use disorder prevalence in small areas using administrative data. Biostatistics (Under Review).

(2023). Massachusetts prevalence of Opioid Use Disorder estimation revisited: Comparing a Bayesian approach to standard capture-recapture methods. American Journal of Epidemiology (Under Revision).

(2023). Modeling recurrent relapse and remitting episodes during MOUD treatment: a tutorial. Medical Decision Making (Under Revision).

(2023). The prevalence of opioid use disorder in Kentucky’s counties: A two-year multi-sample capture-recapture analysis. Drug and Alcohol Dependence.

Cite Link

(2022). Opioid Use Disorder Among Ohio’s Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. American Journal of Epidemiology.

Cite Link

(2022). Medicaid hepatitis C virus treatment policies: impact on testing and treatment in the commercially insured. American Journal of Preventive Medicine.

Cite Link

(2022). Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction.

Cite DOI Link

(2022). Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction.

Cite DOI Link

(2022). Factors associated with opioid-involved overdose among previously incarcerated people in the US: A community engaged narrative review. International Journal of Drug Policy.

Cite Link

(2022). Empirical Calibration of a Simulation Model of Opioid Use Disorder. medRxiv.

PDF Cite Link

(2021). HIV Pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges. AIDS and Behavior.

Cite DOI Link

(2021). Outcomes associated with medications for opioid use disorder among persons hospitalized for infective endocarditis. Clinical Infectious Diseases.

Cite DOI Link

(2021). Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA NETWORK OPEN.

Cite Link

(2020). Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. The American journal of medicine.

Cite Link

(2020). Rapid versus laboratory-based testing for HIV and hepatitis C at a drug detoxification treatment center: a randomized trial. The Journal of infectious diseases.

Cite DOI Link

(2020). HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic. Journal of General Internal Medicine.

Cite Link

(2020). Opioid overdose and inpatient care for substance use disorder care in Massachusetts. Journal of substance abuse treatment.

Cite DOI Link

(2020). Estimation and correction of bias in network simulations based on respondent-driven sampling data. Scientific reports.

Cite Link

(2020). Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons. Clinical Infectious Diseases.

Cite DOI Link

(2019). Hepatitis C virus antibody testing among 13-to 21-year-olds in a large sample of US federally qualified health centers. JAMA.

Cite DOI Link

(2019). Meta-Modelling for Policy Simulations with Multivariate Outcomes. 41st Annual Meeting of the Society for Medical Decision Making.

Cite Link

(2019). Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. Journal of hepatology.

Cite DOI Link

(2019). Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug and alcohol dependence.

Cite DOI Link

(2019). Hepatitis C testing and patient characteristics in Washington State's prisons between 2012 and 2016. American journal of preventive medicine.

Cite DOI Link

(2018). Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture–recapture analysis. American Journal of Public Health.

Cite Link

(2018). Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States. Clinical Infectious Diseases.

Cite DOI Link

(2018). The burden of untreated HCV infection in hospitalized inmates: a hospital utilization and cost analysis. Journal of Urban Health.

Cite Link

(2017). Hepatitis C testing increased among baby boomers following the 2012 change to CDC testing recommendations. Health Affairs.

Cite DOI Link

Fundings & Awards

Fundings

  • Student Fellow Award Funding supported by Boston University Rafik B. Hariri Institute for Computing and Computational Science (2021 - Present)

Honors & Awards

  • Student Travel Award recognized by the International Conference of Health Policy Statistics (2022)
  • Trainee Scholarship awarded by Society for Medical Decision Making Annual Meeting (2022)
  • Scholar Award recognized by the American Public Health Association (2021)
  • Academic Enhancement Award recognized by Boston University Rafik B. Hariri Institute for Computing and Computational Science & Engineering (2021)

Teaching

  • Graduate Teaching Assistant for Data Science and Statistical Modeling in R (2022)
  • Guest lecture for Survival Analysis (2022)

Professional Services

Journal Referees

  • Open Forum Infectious Diseases
  • Journal of Substance Abuse Treatment, Prevention, and Policy
  • Journal of Archives of Suicide Research
  • The American Journal of Applied Scientific Research

Conference Referees

  • Society for Medical Decision Making (SMDM) Annual Meeting
  • American Public Health Association (APHA) Annual Meeting & Expo
  • Models of Infectious Disease Agent Study (MIDAS) Network Annual Meeting

Others

  • Student liaison at American Public Health Association HIV/AIDS Section (2022 - Present)
  • Contributed Session Chair at 2023 International Conference on Health Policy Statistics

Contact